The drug-device combination was designed with a needle that stays hidden during injection and a sensor to detect placement on the skin.
Amgen’s latest product uses a new drug formulation of Enbrel, an injectable biologic approved for patients with chronic conditions like rheumatoid arthritis. The new formulation is associated with less injection site pain compared to the current formulation, Amgen reported.
“As a leader in the inflammation space, we continually strive to innovate to address real needs among the patients we serve. The first step in this is talking and listening to the community, both patients and healthcare professionals, to fully understand the challenges they are facing,” Dr. Sean Harper, Amgen’s EVP of R&D, said in prepared remarks.
“These conversations highlighted the value of features that we believe enhance the patient experience. From there, the Enbrel Mini with AutoTouch and the new formulation, were born.”
The drug-device combo was approved by the FDA in September this year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.